Literature DB >> 7947355

Androgen metabolism in the human prostatic cancer cell line LNCaP.

P Negri-Cesi1, M Motta.   

Abstract

The metabolism of androgens in prostatic carcinoma has not been sufficiently studied so far, mainly because of the difficulty in obtaining human tissue specimens. The availability of LNCaP (lymph node carcinoma of the prostate) cells which retain most of the characteristics of the original carcinoma (dependence on androgens, presence of androgen receptors, production of acid phosphatase, etc.) has allowed the present in vitro study designed to characterize the metabolic pathways through which testosterone (T) is metabolized in malignant cells. LNCaP cells have been incubated in the presence of different labelled androgenic precursors to quantitate the formation of the respective metabolites, as indicators of the specific activities of the enzymes involved in such conversions; whenever possible, the kinetic constants (Km and Vmax) of the enzymes have also been calculated. It has been observed that, when [14C] T is used as substrate, the cells form both dihydrotestosterone (DHT) and androst-4-en-3,17 dione (delta 4) with the prevalence of the latter. When [14C] delta 4 is the substrate, T and 5 alpha-androstan-3,17-dione (5 alpha-A) are found with 5 alpha-A representing the major product. In addition, the cells form diols and 5 alpha-A from [14C]DHT as well as androsterone (A) and DHT from [14C]5 alpha-A; there is a prevalence of diols in the former case, and of A in the latter one. The yields of the different metabolites recovered after 2 h of incubation of the cells with the appropriate labelled substrates are therefore in descending order of magnitude: 5 alpha-A > A > diols > delta 4 > DHT > T. These results are also confirmed by the analysis of the rate of production of the different steroids. Taken together the present results suggest that: (a) qualitatively LNCaP cells possess all the major key enzymes involved in androgen processing; (b) the metabolism of androgens in this cell line resembles quantitatively that found in prostatic cancer tissue; all the metabolic steps which contribute to DHT degradation exceed the ones leading to its accumulation; (c) 5 alpha-reductase shows a significantly higher affinity for delta 4 than for T; (d) LNCaP cells may represent a suitable in vitro model for the study of factors controlling the formation and the degradation of androgens in prostatic carcinoma, thus permitting a better understanding of the metabolic processes involved in prostatic benign or malignant (carcinoma) transformation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947355     DOI: 10.1016/0960-0760(94)90119-8

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

2.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

3.  Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Authors:  Greg N Brooke; Simon C Gamble; Michael A Hough; Shajna Begum; D Alwyn Dart; Michael Odontiadis; Sue M Powell; Flavia M Fioretti; Rosie A Bryan; Jonathan Waxman; Robin Wait; Charlotte L Bevan
Journal:  Mol Cell Proteomics       Date:  2015-02-18       Impact factor: 5.911

4.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09

Review 5.  Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review).

Authors:  Izak Faiena; Eric A Singer; Chris Pumill; Isaac Y Kim
Journal:  Int J Oncol       Date:  2014-09-17       Impact factor: 5.650

Review 6.  Cytoreductive treatment strategies for de novo metastatic prostate cancer.

Authors:  Martin J Connor; Taimur T Shah; Gail Horan; Charlotte L Bevan; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Clin Oncol       Date:  2019-11-11       Impact factor: 66.675

7.  Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity.

Authors:  M F Palin; M Faguy; J G LeHoux; G Pelletier
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

Review 8.  Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.

Authors:  Elahe A Mostaghel
Journal:  Int J Biol Sci       Date:  2014-06-03       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.